Biophytis SA [BPTS] Stock Forecast

Biophytis (NASDAQ: BPTS ) stock is taking off on Thursday after the company revealed results from a recent clinical trial. The big news affecting BPTS stock today comes from a Phase 2/3 study of Sarconeos as a treatment for severe respiratory failure in patients suffering from Covid-19.

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 9, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th and the 12th of March 2023. Professor Suzana Lobo, MD -Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto, São Paulo, Brazil and Investigator of the COVA study in Brazil, will be holding an oralpresentation of the results titled "COVA clinical study:Results from a double-blind, placebo-controlled phase2/3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients.

Penny stocks to watch with news. The post 5 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biophytis (NASDAQ: BPTS ) stock is rocketing higher on Thursday after the company signed a master service agreement with Intsel Chimos. With this agreement, Intsel Chimos will become the Pharmaceutical Operator/Exploitant in France for Sarconeos.

Biophytis SA (NASDAQ: BPTS) said that it is currently assessing FDA comments and recommendations and preparing to submit Phase 2-3 trial designs for sarconeos (BIO101) trial in sarcopenia. Enrollment is expected to start in 2H of 2022 in the SARA Phase 2 trial.

Biophytis SA BPTS has received approval from the ANVISA (Brazilian health authority) for its Expanded Access Program (EAP) to treat hospitalized patients with severe COVID-19 with Sarconeos (BIO101).  Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 29, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today reports the restated financial statements as per the Company's previous announcement on October 7, 2021 for the periods ending December 31, 2019, December 31 2020, June 30 2020 and June 30 2021, with no impact on the Company's cash and cash equivalent as of June 30 2021. 1/ Preliminary remarks Pursuant to the provisions of IAS 8, the Company determined following the review by and discussions with the Company's independent registered public accounting firm, that it is necessary to restate the Company's previously issued consolidated financial statements for the 2019 and 2020 financial years and for the first semester of the financial years 2020 and 2021, in order to make certain corrections required to reflect the proper accounting treatment of the Company's convertible notes.

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announced that the Company's previously issued audited consolidated financial statements for the fiscal years ended December 31, 2019 and 2020 and unaudited consolidated financial statements for the six month periods ended June 30, 2021 and 2020 will be restated to correct the Company's accounting treatment of its convertible notes.

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia.

PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the issuance of 240 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €6 million under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York (United States) for €24 million (the "2020 Atlas Contract").

Biophytis SA is a FR stock and trading under the symbol BPTS

Biophytis SA stock price is $0.4105 today.

Yes, Biophytis SA is a publicly traded company.